Toll-like receptor 4 antagonists - Pipeline Insight, 2024

Toll-like receptor 4 antagonists - Pipeline Insight, 2024

DelveInsight’s, “Toll-Like Receptor 4 (TLR-4) Agonist - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Toll-Like Receptor 4 (TLR-4) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Toll-Like Receptor 4 (TLR-4) Agonist Understanding

Toll-Like Receptor 4 (TLR-4) Agonist: Overview

The activation of toll-like receptor 4 (TLR4) has been proposed to have a major influence on the inflammatory signalling pathways of the intestinal tract. Inhibition of TLR4 has been postulated as an effective way to treat intestinal inflammation. However, there are a limited number of studies looking into the potential of TLR4 antagonism as a therapeutic approach for intestinal inflammation.

Toll-like receptors (TLRs) are type 1 transmembrane proteins belonging to the wider family of pattern recognition receptors, and are responsible for the recognition of a variety of molecular signals, including endogenous damage and pathogen-associated signals, damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), respectively. TLR4 is an intra- and extracellular receptor expressed on endosomes and cytoplasmic membranes, which recognizes PAMPs (flagellin and LPS) and DAMPS (calprotectin, S100A8/9 HMGB1 and HSP70) through its co-receptors MD2 and CD14.

Targeting TLR4 could represent a potential approach to regulate immune responses and treat inflammation. However, any potential therapeutic agent must be able to block the harmful effects of TLR4 activation without negatively affecting the host’s defence functions. Anti-TLR4 therapies present a promising alternative for future innovative treatments for both inflammatory bowel disease and intestinal mucositis.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Toll-Like Receptor 4 (TLR-4) Agonist R&D. The therapies under development are focused on novel approaches for Toll-Like Receptor 4 (TLR-4) Agonist.

Toll-Like Receptor 4 (TLR-4) Agonist Emerging Drugs Chapters

This segment of the Toll-Like Receptor 4 (TLR-4) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Toll-Like Receptor 4 (TLR-4) Agonist Emerging Drugs

• E-5564: Eisai

E-5564 (Eritoran) is a TLR (Toll-Like Receptor) 4 antagonist created with natural product organic synthesis technology. It is a structural analogue of Lipid A which is an activator of endotoxins of bacteria. It is expected to suppress inflammation and increasing in severity caused by COVID-19 by inhibiting the activation of TLR4, which is found in the most upstream position of various cytokine gene expression signaling that causes the cytokine-storm. Development is in collaboration with GCAR (Global Coalition for Adaptive Research).

It is currently in Phase III stage of development and is being developed by Eisai.

• TAK-242: Akaza Bioscience

TAK-242 acts as inhibitor of Toll-like receptor 4. Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. This pan-European study aims to investigate the safety and efficacy of TAK-242, as measured by changes in key biomarkers and 28-day survival rates. The trial will be a randomised, double-blind, placebo-controlled study in patients with Grade 1 or 2 ACLF.

It is currently in Phase II stage of development and is being developed by Akaza Bioscience.

Further product details are provided in the report……..

Toll-Like Receptor 4 (TLR-4) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Toll-Like Receptor 4 (TLR-4) Agonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Toll-Like Receptor 4 (TLR-4) Agonist

There are approx. 10+ key companies which are developing the Toll-Like Receptor 4 (TLR-4) Agonist. The companies which have their Toll-Like Receptor 4 (TLR-4) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Eisai.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Toll-Like Receptor 4 (TLR-4) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Toll-Like Receptor 4 (TLR-4) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 4 (TLR-4) Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 4 (TLR-4) Agonist drugs.

Toll-Like Receptor 4 (TLR-4) Agonist Report Insights

• Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Toll-Like Receptor 4 (TLR-4) Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Toll-Like Receptor 4 (TLR-4) Agonist drugs?
• How many Toll-Like Receptor 4 (TLR-4) Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Toll-Like Receptor 4 (TLR-4) Agonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Toll-Like Receptor 4 (TLR-4) Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Toll-Like Receptor 4 (TLR-4) Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eisai
• Akaza Bioscience
• OPNT-003
• GeNeuro
• MN-166 (ibudilast)
• Orexo

Key Products

• E5564
• TAK-242
• OPNT-003
• Temelimab
• MediciNova
• OX125